ASX stock of the day: Avita Therapeutics share price climbs 8.4% as company redomiciles

After redomiciling to the United States yesterday, the Avita Therapeutics Inc (ASX: AVH) share price is up 8.4% today.

| More on:
CSL share price Digitised bubbles of cells representing ASX biotech shares such as CSL

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

After redomiciling to the United States yesterday, the Avita Therapeutics Inc (ASX: AVH) share price is up 8.4% today.

Avita Medical's ordinary shares were transferred to Avita Therapeutics, based out of the US state of Delaware, via a scheme of arrangements.

What does Avita Therapeutics do? 

Avita Medical is a regenerative medicine company with technology that addresses therapeutic skin restoration. Its RECELL system provides spray-on skin therapy used to treat burn wounds. The company's treatment of vitiligo, traumatic wounds, scar reconstruction, and dermatological aesthetic applications with the use of RECELL is also being assessed. 

Why did Avita Therapeutics redomicile?

The redomiciliation will better align the company's corporate structure with its business operations. Avita derives virtually all of its revenue from the United States. The redomiciliation will likely substantially reduce costs associated with dual financial reporting and related compliance obligations in Australia and the United States. 

What is the effect of the redomiciliation?

The redomiciliation means Avita's primary listing moves from the ASX to the NASDAQ. Its listing on the ASX will be maintained. Avita shareholders effectively exchange their shares in Avita for equivalent securities in the United States entity. Eligible shareholders received 5 Avita US CHESS Depositary Interests (CDI) for every 100 shares they held. 

How has Avita been performing?

Total product sales more than doubled in the March quarter compared to the prior corresponding period. Avita reported total product sales of $5.9 million during the Q3 FY20, up from $2.3 million in Q3 FY19. For the 9 months ending 31 March Avita Medical recorded $15.6 million in product sales, well above the $4.2 million in sales recorded in the 9 months to March 2019. 

The third quarter was Avita Medical's strongest quarter since launching in the United States in January 2019. This reflects strong customer uptake, even with the COVID-19 pandemic beginning toward the end of the quarter. The company has seen consistent growth since the launch of the RECELL system, and has been somewhat insulated from the challenges of the coronavirus pandemic as treatment of burns patients is not elective or deferrable. 

Kate O'Brien owns shares of Avita Medical Limited. The Motley Fool Australia's parent company Motley Fool Holdings Inc. owns shares of Avita Medical Limited. The Motley Fool Australia has recommended Avita Medical Limited. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Market News

The silhouettes of ten people holding hands with their arms raised against the sky, as the sun rises or sets in the background.
Share Gainers

Here are the top 10 ASX 200 shares today

Investors were nervous this Friday, ending the week on a sour note.

Read more »

A businessman looking at his digital tablet or strategy planning in hotel conference lobby. He is happy at achieving financial goals.
Share Market News

Where to invest $5,000 into ASX 200 shares this month

The team at Bell Potter is bullish on these names. But why?

Read more »

Man pointing an upward line on a bar graph symbolising a rising share price.
52-Week Highs

8 ASX 200 shares hitting multi-year highs today

These shares have defied the trend, hitting new price milestones amid a day in the red for the ASX 200.

Read more »

Broker Notes

Brokers name 3 ASX shares to buy today

Here's why brokers are feeling bullish about these three shares this week.

Read more »

A young man punches the air in delight as he reacts to great news on his mobile phone.
Share Gainers

Why EOS, Evolution Mining, Renascor, and Woodside shares are jumping today

These shares are ending the week on a high. But why?

Read more »

Person with thumbs down and a red sad face poster covering the face.
Share Fallers

Why Accent, Cettire, Ioneer, and Pro Medicus shares are dropping today

These shares are ending the week in the red. What's going on?

Read more »

A group of three miners in hard hats and high visibility vests confer at a rocky mining site.
Broker Notes

Up 66% in a year, just how much more upside does Macquarie tip for Perseus Mining shares?

Just how much higher might Perseus Mining shares soar? Here’s what Macquarie had to say about the ASX 200 gold…

Read more »

Rising share price chart.
Broker Notes

Why this exciting ASX 200 share could rise almost 50%

Bell Potter has good things to say about this biopharmaceutical company.

Read more »